ArcherDX

Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib)

Retrieved on: 
Thursday, May 14, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, CDX, CDX, Companion diagnostic, Embryology, Branches of biology, Fetus, Larotrectinib, Vitrakvi® (larotrectinib), Oncology at Bayer, ArcherDX, Bayer

Bayer and ArcherDX, Inc. today announced a global collaboration for the development and commercialization of a next-generation sequencing (NGS)-based companion diagnostic (CDx) for Vitrakvi (larotrectinib).

Key Points: 
  • Bayer and ArcherDX, Inc. today announced a global collaboration for the development and commercialization of a next-generation sequencing (NGS)-based companion diagnostic (CDx) for Vitrakvi (larotrectinib).
  • The collaboration with ArcherDX perfectly complements Bayers CDx strategy and fits our ambition to provide the right treatment to the right patients with cancer.
  • We are pleased to collaborate with Bayer to address their medical need and accelerate access to therapy.
  • If withheld, modify the VITRAKVI dosage when resumed.1
    Embryo-Fetal Toxicity: VITRAKVI can cause fetal harm when administered to a pregnant woman.